Question 1

What is Asher Bio's approach to immunotherapies?

Accepted Answer

Asher Bio is pioneering a new approach with its cis-targeted immunotherapies, which selectively activate only the immune cell types that drive the desired therapeutic response. This innovation addresses the inherent shortcoming of conventional immunotherapies, which indiscriminately act on multiple cell types, resulting in suboptimal efficacy and side effects.

Question 2

What is cis-targeting?

Accepted Answer

Cis-targeting is a novel approach where Asher Bio's immunotherapies engage two molecules on the same immune cell: an immunomodulatory receptor and a specific target that directs the therapy to the desired immune cell type. This allows for a new level of selectivity, with optimized efficacy and minimized toxicity.

Question 3

How does Asher Bio's approach address the limitations of conventional immunotherapies?

Accepted Answer

Conventional immunotherapies indiscriminately act on multiple cell types, resulting in suboptimal efficacy and side effects. Asher Bio's cis-targeted immunotherapies, on the other hand, selectively activate only the immune cell types that drive the desired therapeutic response, addressing this inherent shortcoming.

Question 4

What are the key advantages of Asher Bio's cis-targeted immunotherapy approach?

Accepted Answer

Asher Bio's cis-targeted immunotherapies offer a new level of selectivity, with optimized efficacy and minimized toxicity. By only activating the immunomodulatory receptor when the targeted antigen is present on the same cell, this approach allows for a more precise and effective immune response.

Asher Biotherapeutics

Company Overview

Company Name

Address

Website

Phone

About Asher Biotherapeutics

More Companies in California

Frequently Asked Questions about Asher Biotherapeutics

What is Asher Bio's approach to immunotherapies?

What is cis-targeting?

How does Asher Bio's approach address the limitations of conventional immunotherapies?

What are the key advantages of Asher Bio's cis-targeted immunotherapy approach?

Social Profiles

Key Decision Makers